oaioai:eprints.soton.ac.uk:508324

Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

Authors
Publication date
8 January 2026
Publisher
Southampton Health Technology Assessments Centre

Abstract

This report is a critique of the company’s submission (CS) to NICE from Merck on the clinical effectiveness and cost effectiveness of avelumab (Bavencio) in combination with axitinib (Inlyta) for treating adults with untreated advanced renal cell carcinoma (aRCC). It identifies the strengths and weakness of the CS

    Similar works

    Full text

    thumbnail-image

    Southampton (e-Prints Soton)

    redirect
    oaioai:eprints.soton.ac.uk:508324
    Last time updated on 28/01/2026

    This paper was published in Southampton (e-Prints Soton).

    Having an issue?

    Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.